TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Phase 3 Study in Combination With BMS-790052 and BMS-650032 in Japanese Hepatitis C Virus (HCV) Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Chronic HCV-1b infected patient~* HCV RNA viral load of ≥ 100,000 IU/mL at screening~* Ages 20 to 75 years~* Non-responder to Interferon plus Ribavirin therapy~* Patient who has been excluded from interferon/ribavirin therapy or intolerant for Interferon/Ribavirin therapy~Exclusion Criteria:~Patients who have -~* Hepatocellular carcinoma~* Co-infection with Hepatitis B virus (HBV) or Human Immunodeficiency Virus (HIV)~* Severe or uncontrollable complication

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Daclatasvir + Asunaprevir (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Clinical Standardization Study of the Preferred Acupuncture Treatment Protocol to Treat Functional Constipation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* meeting the diagnosis of Rome III criteria;~* aged from 18 to 75 years old;~* no use of medicine for constipation about 2 weeks before the enrollment, no acupuncture treatment for constipation in the previous 3 months, and never joined any other trial in progress in the previous 3 months;~* volunteered to join this trial and signed the informed consent form~Exclusion Criteria:~* irritable bowel syndrome, organic constipation or secondary constipation caused by endocrine, metabolic, nervous, postoperative diseases, or by drugs;~* constipation with serious cardiovascular, hepatic or renal diseases, cognitive dysfunction, aphasia, mental disorders, or illness which affects the cooperation for examination and treatment;~* women in gestation or lactation period;~* abdominal aortic aneurysm or hepatosplenomegaly, etc.;~* blood coagulation disorders or using anticoagulants regularly such as Warfarin and Heparin;~* cardiac pacemaker carrier.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- deep needling group (Type: EXPERIMENTAL): Acupoints of bilateral Tianshu (ST25), which were located according to WHO Standardized Acupuncture Points Location, were used. After sterilizing the skin, needles of the size of 0.35×0.75mm were inserted into ST25 vertically and slowly without manipulation for about 20\~60mm until piercing into the muscle layer. Paired alligator clips of the electric acupuncture (EA) apparatus were attached transversely to the needle holders of bilateral ST25. EA stimulation lasted for 30 minutes with a dilatational wave of 2/15Hz and current intensity of 0.1\~1mA. Participant's abdominal muscle twitching mildly showed the proper dose. Patients were treated once a day, five times a week for continuous 4 weeks.
- lactulose group (Type: ACTIVE_COMPARATOR): Lactulose Oral Solution was taken orally at the dose of 20\~30ml once every morning after breakfast for continuous 4 weeks. Patients should take lactulose for another 3 months if no severe adverse effect was showed.
- shallow needling group (Type: ACTIVE_COMPARATOR): Bilateral ST25, the same acupoints as deep needling group, were used. After skin disinfection, needles of the size of 0.30×25mm penetrated the skin uprightly for about 5\~9mm into the fat layer without manipulation. The usage of EA apparatus and treatment course were the same as deep needling group.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Intratumoral CAVATAK (CVA21) and Pembrolizumab in Patients With Advanced Melanoma (VLA-011 CAPRA)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects with metastatic or unresectable stage IIIb/c of IV melanoma for whom treatment with pembrolizumab is indicated and who have at least one cutaneous, subcutaneous tumor or palpable lymph node amenable to intratumoral injection.~* At least one tumor must qualify to be an index lesion for modified WHO criteria.~* Subjects must have adequate hematologic, hepatic and renal function.~* ECOG performance status of 0 or 1.~* Anticipated lifespan greater than 12 weeks~Exclusion Criteria:~* Ocular primary tumors.~* Presence of any central nervous system tumor that has not been stable for at least 4 weeks off corticosteroids.~* Tumors lying in mucosal regions or close to an airway, major blood vessel or spinal cord.~* Subjects with active, known or suspected autoimmune or immunosuppressive disease.~* Subjects previously treated with CVA21.~* Subjects requiring systemic treatment with corticosteroids or other immunosuppressive medications within 14 days prior to the first treatment.~* Subject has received chemotherapy within the last 4 weeks prior to first treatment.~* Clinically significant cardiovascular disease.~* Females of childbearing potential must have negative serum or urine pregnancy test.~* Subjects requiring or using other investigational agents while on treatment in this trial.~* History of other malignancy within the last 3 years (with exceptions).~* Active infection requiring systemic therapy.~* Known history of HIV disease, active hepatitis B or hepatitis C.~* History or evidence of other clinically significant disorders that would pose a risk to subject safety.~* Inability to give informed consent and comply with the protocol.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CAVATAK and pembrolizumab (Type: EXPERIMENTAL): Intratumoral CAVATAK administration on trial days 1, 3, 5 and 8 and at 3-weekly intervals up to a maximum of 19 total with intravenous pembrolizumab (2 mg/kg solution) starting on day 8 and continuing every 3 weeks, up to 2 years.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Dexmedetomidine After Thyroidectomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Female patient,~* Aged 20-60 yr,~* ASA physical status 1-2,~* Patients undergoing elective thyroidectomy under general anesthesia~Exclusion Criteria:~* Sighs of difficult airway,~* History of respiratory disease or chronic cough,~* Cardiovascular disease,~* Pregnant or breast-feeding woman

- Gender: FEMALE
- Minimum Age: 20 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Dexmedetomidine (Group D) (Type: EXPERIMENTAL): After induction of anesthesia, anesthesia is maintained with desflurane and remifentanil during thyroidectomy.~Fifteen minutes before the end of surgery, infusion of remifentanil for surgery is discontinued.~Then, dexmedetomidine has started infusion for 15 min (rate of 0.6 ug/kg/hr). Vital signs and complications of testing drugs are measured before and after infusion of testing drugs.~Five minutes before the end of surgery, anesthetic gas (desflurane) is discontinued.~After patient has awake, extubation has done. Extubation time and Recovery time,Cough reflex,Ramsay Sedation Scale, Visual analogue scale, and surgical outcomes such as postoperative bleeding, time to remove drainage and duration of hospital staying, postoperative complications are measured until POD#3.
- Normal Saline (Group N) (Type: PLACEBO_COMPARATOR): After induction of anesthesia, anesthesia is maintained with desflurane and remifentanil during thyroidectomy.~Fifteen minutes before the end of surgery, infusion of remifentanil for surgery is discontinued. Then, normal saline has started infusion for 15 min (same rate as Group D). Vital signs and complications of testing drugs are measured before and after infusion of testing drugs.~Five minutes before the end of surgery, anesthetic gas (desflurane) is discontinued.~After patient has awake, extubation has done. Extubation time and Recovery time,Cough reflex,Ramsay Sedation Scale, Visual analogue scale, and surgical outcomes such as postoperative bleeding, time to remove drainage duration of hospital staying, postoperative complications are measured until POD#3.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety, Tolerability, PK and PD of BI 655075 and Establishment of BI 655075 Dose(s) Effective to Reverse Prolongation of Blood Coagulation Time by Dabigatran

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion criteria:~* Healthy midage male and female volunteers, age =45 and =64 years, BMI range: =18.5 and =29.9 kg/m2~* Healthy elderly male and female volunteers, age =65 and =80 years, BMI range: =18.5 and = 32 kg/m2~* Male and female volunteers with mild renal impairment (CLcrd 60-90 (mL/min)) in relatively good health, age =45 and =80 years, BMI range: =18.5 and =32 kg/m2 Moderate renal impaired (CLcrd =30 to \<60 mL/min according Cockcroft\&Gault formula in relatively good health, age =45 and =80 years, BMI range: =18.5 and =32 kg/m2~Exclusion criteria:~* Any finding of the medical examination (including BP, PR and ECG) deviating from normal and of clinical relevance~* Any evidence of a clinically relevant concomitant disease (other than mild renal impairment in the respective group) A significant disease is defined as a disease which in the opinion of the investigator~* put the volunteer at risk because of participation in the study~* may influence the results of the study~* may influence the volunteer¿s ability to participate in the study~* is not in a stable condition Diabetic, hypercholesterolemia or hypertensive subjects can be entered in this trial if the disease is not significant according to these criteria~* Surgery of the gastrointestinal tract (except appendectomy)~* Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders~* History of relevant orthostatic hypotension, fainting spells or blackouts.~* Chronic or relevant acute infections~* History of relevant allergy/hypersensitivity (including allergy to drug or its excipients)

- Gender: ALL
- Minimum Age: 45 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Study Arms:
- healthy subjects aged 45-64 (Type: EXPERIMENTAL): Sequential Crossover to Placebo or BI 655075
- healthy elderly subjects aged 65-80 year (Type: EXPERIMENTAL): Sequential Crossover to Placebo or BI 655075
- mild renal impairment aged 45-80 years (Type: EXPERIMENTAL): Sequential Crossover to Placebo or BI 655075
- mod renal impairment aged 45-80 years (Type: EXPERIMENTAL): Sequential Crossover to Placebo or BI 655075

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Role of Pain Modulation in GERD Patients Who Failed Standard Dose PPI

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2/PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Currently being treated with a PPI, but continue to experience GERD symptoms (such as heartburn) at least 2 times per week.~Exclusion Criteria:~* Known allergy or intolerance to TCA~* History of serious arrhythmia or use of anti-arrhythmics~* History of seizures~* Subjects with significant co-morbidity, e.g., cardiovascular, respiratory, urogenital, renal, gastrointestinal, hepatic, hematological, endocrine, neurologic or psychiatric~* With evidence or history of drug abuse within the past 6 months~* Erosive esophagitis, esophageal ulceration, peptic stricture, Barrett's esophagus or adenocarcinoma of the esophagus on endoscopy~* History of esophagogastric surgery~* Gastric or duodenal lesions (ulcer, tumor, etc.)~* Women who are pregnant or of childbearing age who are not on contraception~* Patients who are unwilling or unable to provide informed consent~* Insulin dependent diabetes

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Rabeprazole morning/evening placebo bedtime (Type: PLACEBO_COMPARATOR): AciPhex 20 mg BID and once daily placebo
- Rabeprazole breakfast, placebo dinner and bedtime (Type: PLACEBO_COMPARATOR): AcipHex 20 mg once daily and BID placebo
- Rabeprazole breakfast, placebo dinner, nortriptyline bedtime (Type: ACTIVE_COMPARATOR): AcipHex 20 mg once daily, placebo once daily and nortriptyline once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Early TIPS With Polytetrafluoroethylene (PTFE) Covered Stents for Acute Variceal Bleeding in Patients With Advanced Cirrhosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* History of cirrhosis (clinical or by liver biopsy)~* Admission due to acute bleeding from oesophageal or gastric (GOV1 or GOV2) varices~* Child-Pugh Class C (Child-Pugh score less than or equal to 13) or Child-Pugh class B~* Signed written informed consent~Exclusion Criteria:~* Patients not fulfilling inclusion criteria~* Pregnancy or breast-feeding~* Confirmed hepatocellular carcinoma~* Creatinine greater than 3 mg/dl~* Terminal hepatic failure (Child-Pugh score greater than 13)~* Previous treatment with TIPS or combined pharmacological and endoscopic treatment to prevent rebleeding~* Fundal or ectopic gastric variceal bleeding (IGV1 or IGV2)~* Complete portal vein thrombosis or portal cavernoma~* Congestive heart failure New York Heart Association (NYHA) greater than III or medical history of pulmonary hypertension~* Spontaneous recurrent hepatic encephalopathy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- TIPS treatment (Type: EXPERIMENTAL): Initial control of the bleeding episode will be obtained by vasoactive drugs (octreotide, somatostatin or terlipressin), endoscopic band ligation (sclerotherapy if technically difficult or not feasible) and prophylactic antibiotics.TIPS will be performed as soon as possible once the patients are enrolled in the study, always within the first 72 hours after the diagnostic endoscopy (preferably in the first 24 hours).Vasoactive drugs will be continued until the TIPS is performed and antibiotics will be continued for 5-7 days.
- Medical treatment (Type: ACTIVE_COMPARATOR): Initial control of the bleeding episode will be obtained by vasoactive drugs (octreotide, somatostatin or terlipressin), endoscopic band ligation (sclerotherapy if technically difficult or not feasible) and prophylactic antibiotics.Patients will be treated with non-selective beta-blockers (propranolol)on day 5. In case of contraindications or intolerance to beta-blockers, patients will not receive pharmacological treatment (beta-blockers) and the only treatment to prevent rebleeding will be endoscopic band ligation.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: FLIO and the Influence of Oral Lutein Supplementation on Macular Pigment

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subject must be willing to give written informed consent~* Probands 18 years of age or greater~* Both eyes will be assessed in the study~Exclusion Criteria:~* Opacities of ocular media excluding detailed observation of the retina~* Gastrointestinal diseases that could cause disturbance of dietary absorption~* History of lutein supplementation~* Allergy to lutein and zeaxanthin~* Missing compliance

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- AMD (Type: EXPERIMENTAL): None
- healthy control (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Vaccination Adjuved Against Hepatitis B in SNS Workers Typed as no Responders to Conventional Vaccines

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* NHS workers -including university students doing their internships in health centres dependent on the National Health System (inclusion of students is regulated and limited by specific instructions on labour prevention in each autonomous community).~* Criteria defining them as NO responders to the conventional hepatitis B vaccine: anti HBsAb titers \<10 mIU / ml following the application of six doses of conventional vaccine at 20 μg doses (two complete guidelines).~Exclusion Criteria:~* Known allergy to the active substance or any of the other ingredients of the medicinal product (included in section 6 of the product data sheet).~* Subjects that have ever had an allergic reaction to any vaccine against hepatitis B.~* Subjects have a serious infection with fever.~* Subjects for whom informed consent is not obtained.~* Subjects that have not revoked the consent initially signed.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: t

Study Arms:
- Fendrix (Type: EXPERIMENTAL): The primary immunisation consists of 4 separate 0.5 ml doses of FENDRIX administered at the following schedule:~1 month, 2 months and 6 months from the date of the first dose. Once initiated, the primary course of vaccination at 0, 1, 2 and 6 months should be completed with Fendrix, and not with other commercially available HBV vaccine

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Etanercept in New Onset Type 1 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Males and females subjects with T1DM aged 3-18 years~* Positive GAD 65 and/or islet cell antibody~* HbA1c at diagnosis above 6%~* Insulin regimen with 3 injection of insulin daily (as described below)~* White blood count between 3,000-10,000 and platelets \> 100,000~* Normal ALT and AST, creatinine \< 1.8 mg/dl~* T1DM duration equal or less than 4 weeks~Exclusion Criteria:~* Infection requiring IV antibiotics at diagnosis or within past 14 days from study entry~* BMI over 85th percentile for age and gender~* Unstable household~* Unable to provide compliance with study drug, insulin and study visits,~* Evidence of psychiatric disease in the potential study subject and/or primary care taker~* And chronic diseases, including additional autoimmune disorders with the exception of euthyroid autoimmune thyroiditis

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- 1 drug, 2 placebo (Type: EXPERIMENTAL): 1. Etanercept~2. Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Naltrexone for Individuals of East Asian Descent

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* current (i.e., past month) alcohol dependence~* East Asian ethnicity (i.e., Chinese, Korean, or Japanese)~* Prospective genotyping for the A118G SNP of the mu opioid receptor (OPRM1) gene to allow for balanced groups on all three genotypes (AA, AG, GG)~Exclusion Criteria:~* lifetime DSM-IV of drug dependence (other than alcohol or nicotine)~* current use of psychoactive drugs as determined by self-reports and verified using toxicology testing~* lifetime diagnosis of bipolar disorder or any psychotic disorder~* contraindications to an MRI scan (including left handedness)

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Naltrexone (Type: EXPERIMENTAL): Naltrexone 50 mg/day
- Sugar pill (Type: PLACEBO_COMPARATOR): Matched placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Sustainable HIV Risk Reduction Strategies for Probationers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* On probation~* Has received prior drug treatment from an in-prison, residential, or intensive outpatient program~* Can read at the 4th grade level~Exclusion Criteria:~* Does not have 6 months of probation left~* Is not a sex offender~* Does not have a serious mental health diagnosis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- StaySafe (Type: EXPERIMENTAL): Participants are asked to complete 12 brief, self-administered tablet computer sessions designed to improve decision-making around health risk behaviors. Sessions typically take about 10 minutes each to complete and are scheduled prior to or after probationer group or individual appointments at their probation facility. Sessions are scheduled about once per week.
- Comparison (Type: NO_INTERVENTION): Participants are asked to complete baseline, 3-month and 6-month surveys but are not asked to complete StaySafe sessions or other alternate activities.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete